Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2021

May 17, 2021

SELL
$72.25 - $168.95 $137,275 - $321,005
-1,900 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$125.56 - $178.74 $200,896 - $285,984
1,600 Added 533.33%
1,900 $324,000
Q4 2019

Feb 14, 2020

SELL
$76.53 - $135.58 $1.16 Million - $2.06 Million
-15,200 Reduced 98.06%
300 $39,000
Q3 2019

Nov 14, 2019

BUY
$72.81 - $156.91 $917,406 - $1.98 Million
12,600 Added 434.48%
15,500 $1.17 Million
Q2 2019

Aug 14, 2019

BUY
$112.21 - $151.95 $291,746 - $395,069
2,600 Added 866.67%
2,900 $441,000
Q1 2019

May 15, 2019

SELL
$106.67 - $151.68 $21,334 - $30,336
-200 Reduced 40.0%
300 $36,000
Q4 2017

Feb 14, 2018

SELL
$47.64 - $56.75 $166,740 - $198,625
-3,500 Reduced 87.5%
500 $28,000
Q3 2017

Nov 14, 2017

BUY
$35.73 - $47.15 $142,920 - $188,600
4,000
4,000 $181,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.9B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.